IPO registrations (S-1, F-1) · Registrants
Generation Bio Co.
- SEC CIK
- 1733294 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2020-05-22, last 2021-01-04; 2 initial registrations, 2 amendments
- Outcome
- Final prospectus filed 2020-06-12; declared effective 2020-06-11
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Business address
- 301 BINNEY STREET, Cambridge, MA 02142
- EIN
- 81-4301284
- EDGAR entity type
- operating
- Insiders and CEO pay
- Generation Bio Co. on the corporate pages
Offering terms
- Proposed price range
- $18.00–$19.00 per share (S-1/A filed 2020-06-11)
- Final price
- $19.00 per share, within the range (424B4 filed 2020-06-12, an initial public offering)
- Shares sold
- 10,526,316
- Gross proceeds
- $200,000,004 before underwriting discounts and any over-allotment option
- Lead underwriters
- J.P. Morgan; Jefferies; Cowen
- Syndicate
- Wedbush Securities
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: GENERATION BIO CO. EXACT (EIN (EXACT))
- Form D issuer: Generation Bio Co. EXACT (CIK (EXACT))
- SEC filer: Generation Bio Co. EXACT (CIK (EXACT))
- Person page: James E Flynn Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwnerOther))
Filings 11
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2020-05-22 | S-1 | S-1 (registration) | Generation Bio Co. | 0001193125-20-150059 ↗ |
| 2020-06-08 | S-1/A | S-1/A (amendment) | Generation Bio Co. | 0001193125-20-162714 ↗ |
| 2020-06-11 | S-1/A | S-1/A (amendment) | Generation Bio Co. | 0001193125-20-166090 ↗ |
| 2020-06-11 | S-1MEF | S-1MEF (added securities) | Generation Bio Co. | 0001193125-20-166856 ↗ |
| 2020-06-11 | EFFECT | EFFECT (declared effective) | Generation Bio Co. | 9999999995-20-001401 ↗ |
| 2020-06-12 | 424B4 | 424B4 (final prospectus) | Generation Bio Co. | 0001193125-20-167812 ↗ |
| 2021-01-04 | S-1 | S-1 (registration) | Generation Bio Co. | 0001193125-21-000941 ↗ |
| 2021-01-06 | S-1MEF | S-1MEF (added securities) | Generation Bio Co. | 0001193125-21-003388 ↗ |
| 2021-01-06 | EFFECT | EFFECT (declared effective) | Generation Bio Co. | 9999999995-21-000058 ↗ |
| 2021-01-07 | 424B4 | 424B4 (final prospectus) | Generation Bio Co. | 0001193125-21-004249 ↗ |
| 2022-05-09 | EFFECT | EFFECT (declared effective) | Generation Bio Co. | 9999999995-22-001359 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-06-11 | S-1/A | registration statement | $18.00–$19.00 | 10,000,000 | - | 4 | primary document; range, shares headline, cover names 4 | document ↗ | ||
| 2020-06-12 | 424B4 | final prospectus | $19.00 | 10,526,316 | $200,000,004 | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Angelino Mark D. | Officer | Chief Operating Officer; CHIEF OPERATING OFFICER | 5 | 2020–2021 | |
| Artal Group S.A. | TenPercentOwner | 2 | 2020 | ||
| Artal International Management S.A. | TenPercentOwner | 2 | 2020 | ||
| Artal International S.C.A. | TenPercentOwner | 2 | 2020 | ||
| Artal Treasury Ltd | TenPercentOwner | 2 | 2020 | ||
| Atlas Venture Associates Opportunity I, LLC | TenPercentOwner | 7 | 2020–2026 | ||
| Atlas Venture Associates Opportunity I, L.P. | TenPercentOwner | 4 | 2020–2026 | ||
| Atlas Venture Associates X, LLC | TenPercentOwner | 9 | 2020–2026 | ||
| ATLAS VENTURE ASSOCIATES X, L.P. | TenPercentOwner | 9 | 2020–2026 | ||
| Atlas Venture Fund X, L.P. | TenPercentOwner | 7 | 2020–2026 | ||
| Atlas Venture Opportunity Fund I, L.P. | TenPercentOwner | 9 | 2020–2026 | ||
| Casdin Capital, LLC | TenPercentOwner | 2 | 2020 | ||
| Casdin Eli | TenPercentOwner | 2 | 2020 | ||
| Christensen Gustav | Director | 9 | 2020–2026 | ||
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | TenPercentOwnerOther | 2 | 2020 | ||
| Deerfield Mgmt L.P. | TenPercentOwnerOther | 2 | 2020 | ||
| DEERFIELD PARTNERS, L.P. | TenPercentOwnerOther | 2 | 2020 | ||
| DiPalma Stephen J. | Officer | See Remarks | 1 | 2020 | |
| Flynn James E | TenPercentOwnerOther | 2 | 2020 | person page Fuzzy | |
| Invus Public Equities Advisors, LLC | TenPercentOwner | 2 | 2020 | ||
| Invus Public Equities, L.P. | TenPercentOwner | 2 | 2020 | ||
| JONAS JEFFREY M | Director | 9 | 2020–2026 | ||
| Kerr Douglas | Officer | Chief Development Officer; CHIEF MEDICAL OFFICER | 17 | 2020–2024 | |
| MCDONOUGH GEOFF | Director; Director,Officer; Director,Officer,TenPercentOwner | President and CEO; PRESIDENT AND CEO; See Remarks | 31 | 2020–2026 | |
| Minne Pascal | TenPercentOwner | 2 | 2020 | ||
| Nicholson Donald William | Director | 12 | 2020–2026 | ||
| Quinn Anthony G. | Director | 12 | 2020–2026 | ||
| Rhodes Jason P | Director | 15 | 2020–2026 | ||
| Rowland Charles A Jr | Director | 14 | 2020–2026 | ||
| Stanton Matthew | Officer | Chief Scientific Officer; CHIEF SCIENTIFIC OFFICER | 34 | 2020–2025 | |
| Stehman-Breen Catherine | Director | 9 | 2020–2026 | ||
| Stichting Administratiekantoor Westend | TenPercentOwner | 2 | 2020 | ||
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | TenPercentOwner | 2 | 2020 | ||
| Westend S.A. | TenPercentOwner | 2 | 2020 | ||
| Dreyfuss Philip D | TenPercentOwnerOther | 2 | 2020 | ||
| FARALLON CAPITAL MANAGEMENT LLC | TenPercentOwnerOther | 2 | 2020 | ||
| FARALLON PARTNERS L L C/CA | TenPercentOwnerOther | 2 | 2020 | ||
| Fisch Michael B. | TenPercentOwnerOther | 2 | 2020 | ||
| FRIED RICHARD B | TenPercentOwnerOther | 2 | 2020 | ||
| Kim David T | TenPercentOwnerOther | 2 | 2020 | ||
| Linn Michael G | TenPercentOwnerOther | 2 | 2020 | ||
| PATEL RAJIV A | TenPercentOwnerOther | 2 | 2020 | ||
| Roberts Thomas G. Jr. | TenPercentOwnerOther | 2 | 2020 | ||
| Seybold William | TenPercentOwnerOther | 2 | 2020 | ||
| Spokes Andrew J M | TenPercentOwnerOther | 2 | 2020 | ||
| Warren John R. | TenPercentOwnerOther | 2 | 2020 | ||
| WEHRLY MARK C | TenPercentOwnerOther | 2 | 2020 | ||
| Zone Healthcare Holdings, LLC | TenPercentOwnerOther | 2 | 2020 | ||
| Norkunas Matthew | Officer | Chief Financial Officer; CHIEF FINANCIAL OFFICER | 18 | 2020–2025 | |
| Zimmermann Tracy | Officer | Chief Development Officer; CHIEF DEVELOPMENT OFFICER | 18 | 2020–2024 | |
| Cooper Ronald Harold Wilfred | Director | 8 | 2021–2026 | ||
| Paone Antoinette | Officer | CHIEF OPERATING OFFICER | 29 | 2022–2025 | |
| Appelhans Dannielle | Director | 8 | 2022–2026 | ||
| Samayoa Phillip | Officer | CHIEF SCIENTIFIC OFFICER; CHIEF STRATEGY OFFICER | 22 | 2022–2025 | |
| Howze Yalonda | Officer | CHIEF LEGAL OFFICER; INTERIM CEO AND PRESIDENT; INTERIM CEO & PRESIDENT | 15 | 2023–2026 | |
| Conway Kevin John | Officer | Chief Financial Officer; CHIEF FINANCIAL OFFICER | 9 | 2025–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2020-01-14 | Generation Bio Co. | Biotechnology | $111,471,806 | $111,471,806 | 54 | 1 |
| 2018-03-05 | Generation Bio Co. | Biotechnology | $100,370,802 | $100,370,802 | 26 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | GENERATION BIO CO. | MA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | Generation Bio Co. | MA | Form D private offerings | CIK (EXACT) |
| Patent assignee | Generation Bio Co. | MA | Patents (USPTO) | name and state |
| SEC filer | Generation Bio Co. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Generation Bio Co. | MA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | GENERATION BIO CO. | EIN (EXACT) | ||
| Person page | James E Flynn | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwnerOther) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, MA first:
- ERGO SCIENCE CORP MA
- MILLENNIUM PHARMACEUTICALS INC MA
- ESSENTIAL THERAPEUTICS INC MA
- ARQULE INC MA
- ASCENT PEDIATRICS INC MA
- EPIX Pharmaceuticals, Inc. MA
- PRAECIS PHARMACEUTICALS INC MA
- PARATEK PHARMACEUTICALS INC MA
- PREDIX PHARMACEUTICALS HOLDINGS INC MA
- CervoMed Inc. MA
In other datasets, the same topic (Health) in MA:
- Nonprofit: ABBIE M GRIFFIN HOSPITAL FUND (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health